Literature DB >> 7561186

Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group.

A E Brown1, M T Vahey, S Y Zhou, R C Chung, N M Ruiz, D Hofheinz, J R Lane, D L Mayers.   

Abstract

To better understand the biologic meaning and potential clinical utility of p24 antigen measurements in human immunodeficiency virus (HIV) infection, p24 antigen and antibody and HIV RNA were quantitated in parallel. Specimens (n = 311) were analyzed from 74 participants in a zidovudine treatment study. Parallel antigen and RNA measurements revealed the frequent occurrence of two types of discordant results. First, p24 antigen was often not detected in samples with high antibody levels even when > 10(6) RNA copies/mL were present. Second, in specimens in which p24 antigen was detected, the concentration was greater than expected on the basis of HIV RNA values. These results suggest that optimal use of serum p24 antigen values will require consideration of both specific antibody levels and non-virion associated antigen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561186     DOI: 10.1093/infdis/172.4.1091

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Authors:  Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

2.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

3.  Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy.

Authors:  A Lafeuillade; C Poggi; P Pellegrino; N Profizi
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

Review 4.  p24 revisited: a landscape review of antigen detection for early HIV diagnosis.

Authors:  Eleanor R Gray; Robert Bain; Olivia Varsaneux; Rosanna W Peeling; Molly M Stevens; Rachel A McKendry
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

5.  Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection.

Authors:  Caroline Passaes; Héloïse M Delagreverie; Véronique Avettand-Fenoel; Annie David; Valérie Monceaux; Asma Essat; Michaela Müller-Trutwin; Darragh Duffy; Nathalie De Castro; Linda Wittkop; Christine Rouzioux; Jean-Michel Molina; Laurence Meyer; Constance Delaugerre; Asier Sáez-Cirión
Journal:  J Virol       Date:  2021-06-24       Impact factor: 5.103

6.  Towards an ultra-rapid smartphone- connected test for infectious diseases.

Authors:  Valérian Turbé; Eleanor R Gray; Victoria E Lawson; Eleni Nastouli; Jennifer C Brookes; Robin A Weiss; Deenan Pillay; Vincent C Emery; C Theo Verrips; Hiromi Yatsuda; Dale Athey; Rachel A McKendry
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

7.  Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review.

Authors:  Ramachandran Meenakshisundaram; Shah Sweni; Ponniah Thirumalaikolundusubramanian
Journal:  AIDS Res Ther       Date:  2009-11-19       Impact factor: 2.250

8.  HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.

Authors:  L Morris; J M Binley; B A Clas; S Bonhoeffer; T P Astill; R Kost; A Hurley; Y Cao; M Markowitz; D D Ho; J P Moore
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

9.  Perspective on Proteomics for Virus Detection in Clinical Samples.

Authors:  Marica Grossegesse; Felix Hartkopf; Andreas Nitsche; Lars Schaade; Joerg Doellinger; Thilo Muth
Journal:  J Proteome Res       Date:  2020-10-22       Impact factor: 4.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.